Last reviewed · How we verify
Hereditary factor IX deficiency disease
Approved treatments
- Eptacog Alfa · Novo Nordisk
- Recombinant Coagulation Factor Ix · Pfizer Ltd
- Idelvion · CSL Behring GmbH
- Alprolix · Swedish Orphan Biovitrum AB
- Nonacog Alfa (Genetical Recombination) · Pfizer Inc.
Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered - Alprolix · Swedish Orphan Biovitrum
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hereditary factor IX deficiency disease patent landscape — cliff calendar, originator estates, attackable patents
- Hereditary factor IX deficiency disease treatment landscape brief
- Hereditary factor IX deficiency disease treatment updates RSS
Frequently asked questions about Hereditary factor IX deficiency disease
What drugs treat Hereditary factor IX deficiency disease?
Tracked treatments include Eptacog Alfa, Recombinant Coagulation Factor Ix, Idelvion, Alprolix, Nonacog Alfa (Genetical Recombination).
What is the treatment for Hereditary factor IX deficiency disease?
Standard treatment for Hereditary factor IX deficiency disease includes Eptacog Alfa, Recombinant Coagulation Factor Ix, Idelvion, Alprolix, Nonacog Alfa (Genetical Recombination). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hereditary factor IX deficiency disease patent cliff · Hereditary factor IX deficiency disease CI report
- Treatment: Eptacog Alfa · Novo Nordisk
- Treatment: Recombinant Coagulation Factor Ix · Pfizer Ltd
- Treatment: Idelvion · CSL Behring GmbH
- Treatment: Alprolix · Swedish Orphan Biovitrum AB
- Treatment: Nonacog Alfa (Genetical Recombination) · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing